Evidence map›Paper›PMID 38355742›Full record

ArticleScientific reports2024

SARS-CoV-2 infection status in corneal preservation solution and COVID-19 prevalence after corneal transplantation.

Yuki Wasai, Naoyuki Yamada, Nobuaki Ariyoshi, Aiko Haraguchi, Masahiko Funatsu, Masanori Mikuni, Riku Nakamura, Ayano Sakuma, Fumiaki Higashijima, Nanako Iwamoto and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Yuki WasaiDepartment of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 MinamiKogushi, Ube, Yamaguchi, 755-8505, Japan.
Naoyuki YamadaDepartment of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 MinamiKogushi, Ube, Yamaguchi, 755-8505, Japan.
Nobuaki AriyoshiDepartment of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 MinamiKogushi, Ube, Yamaguchi, 755-8505, Japan.
Aiko HaraguchiDepartment of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 MinamiKogushi, Ube, Yamaguchi, 755-8505, Japan.
Masahiko FunatsuDepartment of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 MinamiKogushi, Ube, Yamaguchi, 755-8505, Japan.
Masanori MikuniDepartment of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 MinamiKogushi, Ube, Yamaguchi, 755-8505, Japan.
Riku NakamuraDepartment of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 MinamiKogushi, Ube, Yamaguchi, 755-8505, Japan.
Ayano SakumaDepartment of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 MinamiKogushi, Ube, Yamaguchi, 755-8505, Japan.
Fumiaki HigashijimaDepartment of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 MinamiKogushi, Ube, Yamaguchi, 755-8505, Japan.
Nanako IwamotoDepartment of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 MinamiKogushi, Ube, Yamaguchi, 755-8505, Japan.
Shinichiro TeranishiDepartment of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 MinamiKogushi, Ube, Yamaguchi, 755-8505, Japan.
Mitsuaki NishiokaDivision of Laboratory, Yamaguchi University Hospital, 1-1-1 MinamiKogushi, Ube, Yamaguchi, 755-8505, Japan.
Takahiro YamasakiDivision of Laboratory, Yamaguchi University Hospital, 1-1-1 MinamiKogushi, Ube, Yamaguchi, 755-8505, Japan.
Kazuhiro KimuraDepartment of Ophthalmology, Yamaguchi University Graduate School of Medicine, 1-1-1 MinamiKogushi, Ube, Yamaguchi, 755-8505, Japan. k.kimura@yamaguchi-u.ac.jp.
Yamaguchi University · JPYamaguchi University Hospital · JPKyushu University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The potential risks associated with organs from COVID-19-infected donors were unclear. To determine the SARS-CoV-2 infection status of corneas transplanted during the COVID-19 pandemic, we performed a polymerase chain reaction (PCR) using the corneal preservation solution that was used for corneal transplantation. We also examined the postoperative health status of the recipients. This study included 144 transplants in 143 eyes. Ninety-nine eyes of imported corneas and 10 of the 14 corneas donated in the prefecture were PCR tested at our hospital, and all were SARS-CoV-2 negative. All corneal transplants were performed after confirming their SARS-CoV-2 negativity by a PCR using a corneal preservation solution at our hospital or a nasopharyngeal swab at a previous facility. Despite postoperative steroid administration, no patient developed COVID-19 infection until discharge. Hence, if the donor's nasopharyngeal swab test is SARS-CoV-2 negative, COVID-19 infection in the recipient due to corneal transplantation may be prevented. Since corneal transplant recipients are susceptible to infection due to prolonged steroid administration and are at high risk for severe diseases if infection occurs, SARS-CoV-2 detection testing using nasopharyngeal swabs in donors should be performed.

Indexed as

Corneal TransplantationCOVID-19CorneaHumansPandemicsPrevalenceSARS-CoV-2SteroidsSteroids

Identifiers

PMID38355742
PMCPMC10866865
OpenAlexW4391808551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.